Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.10 USD
Change Today +0.005 / 0.46%
Volume 46.9K
CDXC On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

chromadex corp (CDXC) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/6/15 - $1.72
52 Week Low
12/16/14 - $0.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHROMADEX CORP (CDXC)

Related News

No related news articles were found.

chromadex corp (CDXC) Related Businessweek News

No Related Businessweek News Found

chromadex corp (CDXC) Details

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. It offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; and supplies reference standards, materials, and kits to conduct quality control of raw materials and consumer products, as well as supplies fine chemicals and phytochemicals. The company also provides a range of contract services ranging from routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products to elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Its products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins, which are secondary plant metabolites for use as candidates in the pharmaceutical, dietary supplement, and food colorants industries. The company markets and sells its products to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries directly in the United States and Canada; and through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.

67 Employees
Last Reported Date: 03/19/15

chromadex corp (CDXC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $305.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $249.2K
Chief Operating Officer
Total Annual Compensation: $179.0K
Compensation as of Fiscal Year 2014.

chromadex corp (CDXC) Key Developments

ChromaDex Announces Board Changes

ChromaDex Corp. announced that Rob Fried has joined the company's Board of Directors as an Independent Director. Mr. Fried, age 56, served as Chairman of the Board of Directors of IDI Inc. from 2011 until June 2015. ChromaDex also announced the resignation of Glenn Halpryn from its board. The total number of board members now stands at seven, of which the majority is independent.

ChromaDex Corporation Enters into Amendment to the Loan and Security Agreement

On June 17, 2015, ChromaDex Corporation and its subsidiaries, Hercules Technology II, L.P., as lender and Hercules Technology Growth Capital Inc., as agent entered into Amendment No. 1 to the Loan and Security Agreement entered into by the parties on September 29, 2014. The terms of the Agreement provided the company with access to a term loan of up to $5 million. The first $2.5 million of the term loan was funded at closing. The remaining $2.5 million of the term loan was to be drawn down in part or in full at option at any time but no later than July 31, 2015. The first advance and second advance, if any, were to be repaid in equal monthly installments through the loan's maturity on April 1, 2018, following an initial interest-only period that was to conclude on October 31, 2015. Pursuant to the Amendment, the parties agreed that the interest only period shall be extended to March 31, 2016, provided however that if the company's consolidated revenue is equal to or greater than $11.5 million for the six months ending December 31, 2015, then the interest-only period shall be extended to June 30, 2016. The Amendment became effective on June 18, 2015 upon the funding of the full amount of the $2.5 million second advance and payment of a nonrenewable facility fee of $15,000 to the Agent. Except as amended by the Amendment, the terms and provisions of the Agreement remain in full force and effect.

ChromaDex Corp. Announces Collaborative Human Clinical Study on NIAGEN(R) with the University of Colorado Boulder

ChromaDex Corp. announced that a collaborative human clinical study on NIAGEN® (Nicotinamide Riboside—NR) is underway at the University of Colorado Boulder. ChromaDex's patented ingredient NIAGEN® is the first and only commercially available form of nicotinamide riboside (NR), a naturally occurring vitamin B3 metabolite found in milk. This placebo controlled, double-blind, randomized, cross-over study will assess the potential benefits of daily NIAGEN® supplementation over the course of 6 weeks. Endpoints that will be assessed in this study include physical function, cardiorespiratory fitness and overall metabolism. This new study will build upon the results of ChromaDex's first successful clinical trial which demonstrated that a single oral dose of NIAGEN® is a safe, effective nicotinamide adenine dinucleotide (NAD+) precursor in humans. ChromaDex will provide NIAGEN® supplements for the study along with matched-placebo control pills. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy. In recent years, NAD+ has been shown to be essential in supporting healthy cellular metabolism including the efficient conversion of blood glucose into energy. As organisms age, NAD+ levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. Low NAD+ levels limit activity of a group of enzymes called sirtuins, which are believed to play a key role in longevity. NAD+ levels also can be depleted by lifestyle choices such as overeating and lack of exercise. By boosting NAD+, NR can increase mitochondrial health and induce creation of new mitochondria.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXC:US $1.10 USD +0.005

CDXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eurofins Scientific SE €299.05 EUR -3.70
Sigma-Aldrich Corp $139.61 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation CDXC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book 31.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHROMADEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at